Page 2 - Kaplan Meier News Today

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.

BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...

CHICAGO — The performance of less frequent imaging and bone marrow biopsies than required by clinical trials in patients with follicular lymphoma did not impact PFS, according to data presented at ASCO Annual Meeting.“We do conclude from this that we should consider decreasing the imaging requirements in clinical trials enrolling patients with follicular lymphoma,” Sarah

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes...

Universally Available Gilles-Eric Séralini, , Robin Mesnage, Nicolas Defarge, Steeve Gress University of Caen, Institute of Biology, EA2608, CRIIGEN and Network on Risks, MRSH-CNRS, Esplanade de la Paix, 14032 Caen Cedex, France Didier Hennequin University of Caen, Network on Risks, MRSH-CNRS, Bd Maréchal Juin, 14032 Caen Cedex, France Emilie Clair University of Caen, Institute of…

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies.

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity, confirmed objective response rate

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary,...

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...